TRIPOINT THERAPEUTICS LLC

SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics

These tablets are indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older.